Hemoglobinuria, Paroxysmal - 8 Studies Found

Completed : Study of High Dose Cyclophosphamide in Patients With Severe Aplastic Anemia and Paroxysmal Nocturnal Hemoglobinuria
:
  • Aplastic Anemia
  • Paroxysmal Hemoglobinuria, Nocturnal

: 1999-10-18
:
  • Drug: cyclophosphamide
  • Drug: filgrastim
Completed : Peripheral Blood Stem Cell Transplantation (PBSCT)From Haploidentical Related Donors
:
  • Hematologic Neoplasms
  • Anemia, Aplastic
  • Myeloid Malignancy
  • Inherited Bone Marrow Failure Syndrome

  • : 2016-11-04
    : Other: follow up
Enrolling by invitation : The Impact of Red Cell Age on Product Utilization in the Chronically Transfused Outpatient Population
: Bone Marrow Failure Syndrome
: 2015-03-05
:
  • Other: Fresh Human Red Blood Cells

Enrolling by invitation : Eltrombopag for Enhancing Platelet Engraftment in Adult Patients Undergoing Cord Blood Transplantation
:
  • Hematological Malignancy
  • Bone Marrow Failure Syndrome

: 2012-12-06
: Drug: Eltrombopag From day +1, start eltrombopag 100 mg/d.
Active, not recruiting : Peripheral Blood Stem Cell Transplantation Using the CliniMACS Device
:
  • Malignant Diseases (ie, Leukemia, MDS, Lymphoma)
  • Non-malignant Diseases (ie, Bone Marrow Fai
    : 2010-02-17
    :
    • Device: CliniMACS (CD+3, CD+19 depletion)

Recruiting : Phase 2 Safety and Efficacy Study of RA101495 to Treat PNH Patients
: Paroxysmal Nocturnal Hemoglobinuria (PNH)
: 2017-03-08
: Drug: RA101495 0.3mg/kg subcutaneously (SC) at Day 1 (loading dose) followed by a starting maintenance d
Recruiting : Phase 2 Safety and Efficacy Study of RA101495 to Treat PNH Patients Who Have an Inadequate Response to Eculizumab
: Paroxysmal Nocturnal Hemoglobinuria (PNH)
: 2017-01-20
: Drug: RA101495 0.3mg/kg subcutaneously (SC) at Day 1 (loading dose) followed by a starting maintenance d